MULTICENTER PHASE II NEOADJUVANT AND ADJUVANT STUDY OF ALECTINIB ENTRECTINIB OR VEMURAFENIB PLUS COBIMETINIB IN PATIENTS WITH STAGES I-III NON-SMALL CELL LUNG CANCER WITH ALK ROS1 NTRK OR BRAF V600E MOLECULAR ALTERATIONS

Brief description of study

The purpose of the trial is to determine the efficacy and safety of drugs in patients with untreated non-small cell lung cancer (NSCLC) tumors. In this study, patients will receive alectinib or entrectinib or cobimetinib plus vemurafenib before surgical resection depending on the presence of the corresponding molecular alteration. We want to know if taking the study drug before surgery may shrink the tumor, making it easier for the surgeon to distinguish between normal and cancerous tissue. After this, this will help the doctor decide which treatment plan is best post-surgery.


Clinical Study Identifier: s19-00730
ClinicalTrials.gov Identifier: NCT04302025
Principal Investigator: Elaine Shum.
Other Investigators: Stephanie H. Chang, Samantha VanMaanen, Carol M Lee, Salman Rafi Punekar, Jessica Wang, Sally Lau, Joshua K Sabari, Amie J. Kent, David Mendoza, Natalia Cherkassky, Benjamin Cooper, Avital Benson, Andre L Moreira, Melissa L Martinez, Jonathan B Kahn, Vamsidhar Velcheti.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.